medigraphic.com
Sociedad Mexicana de Dermatología y Academia Mexicana de Dermatología.

2019, Número S1

Dermatol Rev Mex 2019; 63 (S1)


Tratamiento farmacológico tópico en pacientes con acné

Sánchez-Dueñas LE, Tovar-Garza A

Idioma: Español
Referencias bibliográficas: 55
Paginas: 33-40
Archivo PDF: 470.88 Kb.


RESUMEN

El acné es una de las causas más comunes de consulta dermatológica que afecta negativamente la calidad de vida de los pacientes. El tratamiento tópico es fundamental para el manejo del acné comedónico y acné inflamatorio leve a severo. El objetivo de este estudio fue revisar la bibliografía acerca de los tratamientos tópicos en el manejo del acné leve a severo. Se realizó una revisión en Google, Google Scholar y Pubmed de febrero a marzo 2018, utilizando las siguientes palabras clave: acné, tretinoína, adapaleno, tazaroteno, peróxido de benzoilo, eritromicina, clindamicina, dapsona, entre otras. Se incluyeron estudios doble-ciego con distribución al azar, controlados con placebo, así como guías de tratamiento y artículos de revisión en el idioma inglés y español. Los retinoides tópicos y el peróxido de benzoilo se recomiendan para el tratamiento del acné comedónico. En el manejo del acné leve a severo se recomiendan combinaciones de peróxido de benzoilo con clindamicina o adapaleno, así como antimicrobianos y retinoides tópicos solos o en combinación con antibióticos orales. Los retinoides tópicos son la piedra angular para el tratamiento del acné comedónico. El acné inflamatorio leve a severo debe manejarse con tratamientos tópicos combinados, como el peróxido de benzoilo con clindamicina o adapaleno.

REFERENCIAS (EN ESTE ARTÍCULO)

  1. Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, Bowe WP, Graber EM, Harper JC, Kang S, Keri JE. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016;74(5):945-73.

  2. González VS, Webster RL. Acné juvenil inflamatorio. Evaluación de la calidad de vida con la encuesta SF-36. Rev Cent Dermatol Pascua 2007;16(1):7-13.

  3. Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewigman B, Bowman M. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract 2004;17(1):59-67.

  4. Wolverton SE. Comprehensive dermatologic drug therapy. 3rd ed. Elsevier Health Sciences 2012;507-17.

  5. Webster G, Cargill DI, Quiring J, Vogelson CT, Slade HB. A combined analysis of 2 randomized clinical studies of tretinoin gel 0.05% for the treatment of acne. Cutis 2009;83(3):146-54.

  6. Eichenfield LF, Jarratt M, Schlessinger J, Kempers S, Manna V, Hwa J, Liu Y, Graeber M. Adapalene 0.1% lotion in the treatment of acne vulgaris: results from two placebocontrolled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol 2010;9(6):639-46.

  7. Cunliffe WJ, Caputo R, Dreno B, Förström L, Heenen M, Orfanos CE, Privat Y, Aguilar AR, Meynadier J, Alirezai M, Jablonska S. Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and US multicenter trials. J Am Acad Dermatol 1997;36(6):S126-34.

  8. Tirado‐Sánchez A, Espíndola YS, Ponce‐Olivera RM, Bonifaz A. Efficacy and safety of adapalene gel 0.1% and 0.3% and tretinoin gel 0.05% for acne vulgaris: results of a singlecenter, randomized, double‐blinded, placebo‐controlled clinical trial on Mexican patients (skin type III–IV). J Cosmet Dermatol 2013;12(2):103-7.

  9. Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. Cutis 1999;63(6):349-54.

  10. Fulton JE, Farzad‐Bakshandeh A, Bradley S. Studies on the mechanism of action of topical benzoyl peroxide and vitamin A acid in acne vulgaris. J Cutan Pathol 1974;1(5):191-200.

  11. Mills OH, Kligman AM, Pochi P, Comite H. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol 1986;25(10):664-7.

  12. Kawashima M, Hashimoto H, Alio Sáenz AB, Ono M, Yamada M. Is benzoyl peroxide 3% topical gel effective and safe in the treatment of acne vulgaris in Japanese patients? A multicenter, randomized, double‐blind, vehicle‐controlled, parallel‐group study. J Dermatol 2014;41(9):795-801.

  13. Kawashima M, Nagare T, Doi M. Clinical efficacy and safety of benzoyl peroxide for acne vulgaris: between Japanese and Western patients. J Dermatol 2017; 44(11):1212-18.

  14. Lamel SA, Sivamani RK, Rahvar M, Maibach HI. Evaluating clinical trial design: systematic review of randomized vehicle-controlled trials for determining efficacy of benzoyl peroxide topical therapy for acne. Arch Dermatol Res 2015;307(9):757-66.

  15. Kuhlman DS, Callen JP. A comparison of clindamycin phosphate 1 percent topical lotion and placebo in the treatment of acne vulgaris. Cutis 1986;38(3):203-6.

  16. Caused PC. Topical clindamycin phosphate. Arch Dermatol 1986;122:583-4.

  17. Milstone EB, McDonald AJ, Scholhamer CF. Pseudomembranous colitis after topical application of clindamycin. Arch Dermatol 1981;117(3):154-5.

  18. Mills Jr O, Thornsberry C, Cardin CW, Smiles KA, Leyden JJ. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Derm Venereol 2002;82(4):260-5.

  19. Jones EL, Crumley AF. Topical erythromycin vs blank vehicle in a multiclinic acne study. Arch Dermatol 1981;117(9):551- 3.

  20. Shalita AR, Smith EB, Bauer E. Topical erythromycin v clindamycin therapy for acne: A multicenter, double-blind comparison. Arch Dermatol 1984;120(3):351-5.

  21. Alexis AF, Cook-Bolden F, Lin T. Treatment of moderate-tosevere acne vulgaris in a Hispanic population: a post-hoc analysis of the efficacy and tolerability of clindamycin 1.2%/benzoyl peroxide 3.75% gel. J Clin Aesthet Dermatol 2017;10(6):36.

  22. Xu JH, Lu QJ, Huang JH, Hao F, Sun QN, Fang H, Gu J, Dong XQ, Zheng J, Luo D, Li FQ. A multicentre, randomized, single‐blind comparison of topical clindamycin 1%/benzoyl peroxide 5% once‐daily gel versus clindamycin 1% twice‐daily gel in the treatment of mild to moderate acne vulgaris in Chinese patients. J Eur Acad Dermatol Venereol 2016;30(7):1176-82.

  23. Eichenfield LF, Krakowski AC. Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. J Drugs Dermatol 2012;11(7):818-24.

  24. Tschen EH, Katz HI, Jones TM, Monroe EW, Kraus SJ, Connolly MA, Levy SF. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis 2001;67(2):165-9.

  25. Dreno B, Tan J, Rivier M, Martel P, Bissonnette R. Adapalene 0.1%/benzoyl peroxide 2.5% gel reduces the risk of atrophic scar formation in moderate inflammatory acne: a split‐face randomized controlled trial. J Eur Acad Dermatol Venereol 2017;31(4):737-42.

  26. Brodell RT, Schlosser BJ, Rafal E, Toth D, Tyring S, Wertheimer A, Kerrouche N, Bucher D. A fixed-dose combination of adapalene 0.1%–BPO 2.5% allows an early and sustained improvement in quality of life and patient treatment satisfaction in severe acne. J Dermatolog Treat 2012;23(1):26-34.

  27. Tan J, Gollnick HP, Loesche C, Ma YM, Gold LS. Synergistic efficacy of adapalene 0.1%-benzoyl peroxide 2.5% in the treatment of 3855 acne vulgaris patients. J Dermatolog Treat 2011;22(4):197-205.

  28. Gold LS, Tan J, Cruz-Santana A, Papp K, Poulin Y, Schlessinger J, Gidner J, Liu Y, Graeber M. A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. Cutis 2009;84(2):110-6.

  29. Del JR, Stein LG, Johnson SM, Rueda MJ, Baldwin H, Lain EL, Landis M, Rendon M, Tanghetti E, Weiss J. Efficacy and safety of adapalene 0.3%/benzoyl peroxide 2.5% gel plus oral doxycycline in subjects with severe inflammatory acne who are candidates for oral isotretinoin. J Drugs Dermatol 2018;17(3):264-73.

  30. Cunliffe WJ, Holland KT. Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Der Venereol Suppl (Stockh) 1989;143:31-4.

  31. Katsambas A, Graupe K, Stratigos J. Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Derm Venereol Suppl (Stockh) 1989;143:35-9.

  32. Draelos ZD, Carter E, Maloney JM, Elewski B, Poulin Y, Lynde C, Garrett S. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol 2007;56(3):439-e1.

  33. Tanghetti E, Harper JC, Oefelein MG. The efficacy and tolerability of dapsone 5% gel in female vs male patients with facial acne vulgaris: gender as a clinically relevant outcome variable. J Drugs Dermatol 2012;11(12):1417-21.

  34. Shalita AR. Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Clin Ther 1989;11(2):264-7.

  35. Shalita AR, Smith JG, Parish LC, Sofman MS, Chalker DK. Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. Int J Dermatol 1995;34(6):434-7.

  36. Khodaeiani E, Fouladi RF, Amirnia M, Saeidi M, Karimi ER. Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris. Int J Dermatol 2013;52(8):999-1004.

  37. Hurley HJ, Shelley WB. Special topical approach to the treatment of acne. Suppression of sweating with aluminum chloride in an anhydrous formulation. Cutis 1978;22(6):696-703.

  38. Hjorth N, Storm D, Dela K. Topical anhydrous aluminum chloride formulation in the treatment of acne vulgaris: a double-blind study. Cutis 1985;35(5):499-500.

  39. Bagatin E, Florez-White M, Arias-Gomez MI, Kaminsky A. Algorithm for acne treatment: Ibero-Latin American consensus. An Bras Dermatol 2017;92(5):689-693.

  40. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol 2003;49:S200-210.

  41. Kaminsky A, Florez-White M. Acné. Un enfoque global. 3a ed. Buenos Aires: Libro Digital, EPUB. Colegio Iberolatinoamericano de Dermatología (CILAD), 2015;128-163.

  42. Czernielewski J, Michel S, Bouclier M, et al. Adapalene biochemistry and the evolution of a new topical retinoids for treatment of acne. J Eur Acad Dermatol Venereol 2001;15(suppl. 3):5-12.

  43. Galvin SA, Gilbert R, Baker M, Guibal F, Tuley MR. Comparative tolerance of adapalene 0,1% gel and six different tretinoin formulations. Br J Dermatol 1998;(52):34-40.

  44. Lucky AW, Cullen SI, Jarratt MT. Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter double-blind parallel study. J Am Acad Dermatol 1998;S17-S23.

  45. Quigley JW, Bucks DA. Reduced skin irritation with tretinoin containing polyolprepolymer-2, a new topical tretinoin delivery system: a summary of preclinical and clinical investigations. J Am Acad Dermatol 1998;38:S5-S10.

  46. Anadolu RY, Sen T, Tarimci N, et al. Improved efficacy and tolerability of retinoic acid in acne vulgaris: a new topical formulation with cyclodextrin complex psi. J Eur Acad Dermatol Venereol 2004;18:416-21.

  47. Wolf JE. An update of recent clinical trials examining adapalene and acne. J Eur Acad Dermatol Venereol 2001;3:23-29.

  48. Cunliffe WJ, Poncet M, Loesche C, et al. A comparison of the efficacy and tolerability of adapalene 0,1% gel versus tretinoin 0,0255 gel in patients with acne vulgar-is: a meta-analysis of five randomized trials. Br J Dermatol 1998;139(52):48-56.

  49. Lassus A. Local treatment of acne. A clinical study and evaluation of the effects of different concentrations of benzoyl peroxide in gel. Curr Med Res Opin 1981;7:370-4.

  50. Fyrand O, Jakobsen HB. Water-based versus alcohol-based benzoyl peroxide preparations in the treatment of acne vulgaris. Dermatologica 1986;172:263-7.

  51. Taylor GA and Shalita AR. Benzoil peroxide-based combination therapies for acne vulgaris: a comparative review. Am J Clin Dermatol 2004;5(4):261-265.

  52. Wolf JE, Kaplan D, Graus SJ, Loven KH, Rist T, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J Am Acad Dermatol 2003;49:S211-S217.

  53. Gollnick HPM, Draelos Z, Glen MJ, Rosoph LA et al. Adapalene- benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol 2009;161:1180-1189.

  54. Thiboutot D. Versatility of azelaic acid 15% gel in treatment of inflammatory acne vulgaris. J Drugs Dermatol 2008;7(1):13-6.

  55. Scheinfeld N. Aczone, a topical gel formulation of the antibacterial, anti-inflammatory dapsone for the treatment of acne. Curr Opin Investig Drugs 2009;10:474-481.




2020     |     www.medigraphic.com